<DOC>
	<DOCNO>NCT00534508</DOCNO>
	<brief_summary>This study design increase understanding pharmacokinetics tacrolimus affected skin atopic dermatitis patient follow repeated topical application tacrolimus ointment 0.1 % .</brief_summary>
	<brief_title>Distribution Tacrolimus Skin , Atopic Dermatitis</brief_title>
	<detailed_description>The study conduct out-patient basis , patient self-administering ointment twice daily home . However , Days 1 14 single application ointment apply Investigator his/her designee clinic . An area affect skin select skin biopsy sufficient size 5 biopsy sample . The biopsy sample take lesion ( ) possible adjacent lesion anatomical area time . All area select treatment treat tacrolimus ointment 0.1 % period two week follow period one week . Two pharmacokinetic profile ( Days 1 14 ) five skin biopsy sample ( Days 1 , 2 , 15 , 18 21 ) take .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Using Hanifin Rajka Criteria , patient diagnosis moderate severe atopic dermatitis Using Rajka Langeland grade system , patient 's atopic dermatitis score least 4.5 ( moderate severe ) Patient serious skin disorder atopic dermatitis . Patient history eczema herpeticum ( define acute disseminate cutaneous herpes simplex type 1 2 infection associate constitutional symptom like fever , headache , malaise , regional generalise lymphadenopathy individual eczema ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Skin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>dermatitis , atopic</keyword>
</DOC>